A selection of major announcements

1. Ping An of China: The cumulative premium income from January to November increased 4.5% year on year

$PING AN (02318.HK)$The announcement said that in the first 11 months of 2023, the company achieved a cumulative total of 738,378 billion yuan (RMB, same below), an increase of 4.5% over the previous year. Among them, Ping An Life Insurance's original premium income was 433.949 billion yuan, up 6.8% year on year; Ping An Insurance's original premium income was 273.647 billion yuan, up 1.4% year on year.

2. China People's Insurance: The cumulative premium income from January to November increased 7.3% year on year

$PICC GROUP (01339.HK)$The announcement said that in the first 11 months of 2023, the company achieved a total of 613.226 billion yuan in original premium income, an increase of 7.3% over the previous year. In the first 11 months, we received original premium income of 472.7 billion yuan, 97.267 billion yuan and 43.259 billion yuan respectively through People's Insurance Financial Insurance, People's Insurance Life Insurance, and People's Insurance Health, up 6.8%, 9.7%, and 8.1% year-on-year respectively.

3. China Financial Insurance: The cumulative premium income from January to November increased 6.8% year on year

$PICC P&C (02328.HK)$It was announced that in the first 11 months of 2023, the company achieved a cumulative total of 472.7 billion yuan in premium income, an increase of 6.8% over the previous year.

4. Xiansheng Pharmaceutical's COVID-19 drugs are included in the medical insurance catalogue

$SIMCERE PHARMA (02096.HK)$According to the announcement, the Group's innovative drug Xianoxin® for the treatment of adult patients with mild to moderate novel coronavirus infection (COVID-19) has been officially included in the new national medical insurance drug catalogue.

5. The number of new overseas contracts signed by China Metallurgical in November increased by more than 20%

$MCC (01618.HK)$It was announced that the amount of new contracts signed in the first 11 months of this year was 1.19 trillion yuan, an increase of 2.5% over the same period last year, of which the amount of new overseas contracts signed was 37.55 billion yuan, an increase of 22.6% over the previous year.

Operation News

$ZA ONLINE (06060.HK)$: The total amount of original premium income in the first 11 months was about 27.344 billion yuan, up 26.6% year on year

$MTR CORPORATION (00066.HK)$: Signed a construction contract for the Tuen Mun South Extension Project at a contract cost of approximately HK$6.221 billion

Pharmaceutical Innovation

$MEDBOT-B (02252.HK)$: The R-ONE vascular intervention robot has been approved for marketing by the National Drug Administration

$LIVZON PHARMA (01513.HK)$This time, a total of 190 products were included in the medical insurance catalogue

$JUNSHI BIO (01877.HK)$: Tuoyi's new indications and Mindewei are included in the new version of the national health insurance catalogue

$SINO BIOPHARM (01177.HK)$: Seven products including “ibergustine alpha injection (third-generation long-acting G-CSF)” were added to the national health insurance catalogue

$HENLIUS (02696.HK)$: HLX13 (recombinant anti-CTLA-4 whole-human monoclonal antibody injection) of ipimumab antibiotic analogue HLX13 (recombinant anti-CTLA-4 whole-human monoclonal antibody injection) in healthy Chinese male subjects completed administration of the first case of the subject

$SIMCERE PHARMA (02096.HK)$: Xianoxin, an innovative anti-COVID-19 drug, is included in the new national medical insurance drug catalogue

$SHANDONG XINHUA (00719.HK)$: Levoamlodipine benzenesulfonate tablets (2.5mg) obtained a drug registration certificate

Buyback News

$TENCENT (00700.HK)$Repurchase of 1.3 million shares at a cost of HK$400 million on December 13

$AIA (01299.HK)$Repurchase of 2.129,800 shares at a cost of HK$135 million on December 13

$LI NING (02331.HK)$On December 13, 5.5 million shares were repurchased at a cost of HK$103 million

$WUXI BIO (02269.HK)$Repurchase of 3.32 million shares at a cost of HK$92.399 million on December 13

$SINOPEC CORP (00386.HK)$On December 13, 11.682 million shares were repurchased at a cost of HK$44.707 million

$ESR (01821.HK)$Repurchase of 3 million shares at a cost of HK$28.47 million on December 13

$KUAISHOU-W (01024.HK)$On December 13, 500,000 shares were repurchased at a cost of HK$27.08 million

$POP MART (09992.HK)$On December 13, 180,000 shares were repurchased at a cost of HK$3.6181,000

Editor/Corrine